Fresenius is showing early signs of recovery, with improved profitability and a simplified structure, making it a promising investment despite past delays. The company's divestments and deleveraging efforts have strengthened its financials, with a forecasted 60-70% RoR over the next three years. Fresenius is expected to resume dividend payments and achieve double-digit EPS growth, supported by strong performance in its Kabi and Helios segments.